Last update: Aug. 4, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Anti-inflammatory and immunomodulator used in the treatment of psoriasis and in relapsing forms of multiple sclerosis.
Topical and oral administration every 12 hours
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution and short half-life) make it unlikely that milk would pass through in significant quantities (Almas 2016).
Possible side effects are rare and generally not serious, with no immunosuppressive effects or higher frequency of infections (EMA 2017, AEMPS 2015).
Although contraindicated in breastfeeding (Cree 2013), more recently various medical societies and / or expert consensus consider the use of this medication probably safe during breastfeeding (Alroughani 2016, Briggs 2015).
Exposure can be minimized by 90% waiting 3 hours to breastfeed again after taking the medication.
Until there is more published data on this drug in relation to breastfeeding, known safer alternatives may be preferable (Cree 2013), especially during the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM